Bladder cancer (BCa) is a common urinary tumour that is biologically and clinically heterogeneous.1, 2 The recurrence of non‐muscle‐invasive bladder cancer (NMIBC) is very frequent; nevertheless, once it progresses into muscle‐invasive bladder cancer (MIBC), the prognosis is poor.2, 3 Defects in the p53 pathway contribute to diagnosis and therapy difficulties as well as adverse clinical outcome in BCa, which represents an urgent clinical need with few breakthroughs in treatment in the last ten years.4, 5. This evidence concerns the gene TP53 and urinary bladder carcinoma.